---
title: "Top Executive Makes Bold Move in Alpha Tau Medical’s Latest Insider Trade"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292001231.md"
description: "Alpha Tau Medical CFO Raphi Levy sold 2,270 shares for $31,780 on July 7, 2026. The company recently received FDA clearance for its REGAIN glioblastoma trial and reported safe international device use. Despite positive regulatory milestones and a 'Buy' technical signal with YTD gains of 174%, Spark rates the stock Neutral due to weak financials, including zero revenue and significant cash burn."
datetime: "2026-07-08T02:03:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292001231.md)
  - [en](https://longbridge.com/en/news/292001231.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292001231.md)
---

# Top Executive Makes Bold Move in Alpha Tau Medical’s Latest Insider Trade

New insider activity at Alpha Tau Medical Ltd ( (DRTS) ) has taken place on July 7, 2026.

Alpha Tau Medical Ltd has reported an insider transaction by its Chief Financial Officer, Raphi Levy, who sold 2,270 shares of the company’s stock. This disposal of shares amounted to a total value of $31,780, reflecting a notable move in the company’s executive trading activity.

Alpha Tau Medical shares have been driven by regulatory and clinical milestones, including FDA clearance to complete enrollment in its REGAIN glioblastoma trial after strong interim safety and efficacy data, and the first international brain applicator use in Israel showing safe Alpha DaRT delivery. Governance approvals at the AGM reinforced leadership stability, while analysts’ outlooks emphasize promising oncology technology and regulatory momentum but balance this against ongoing cash burn and lack of current revenue.

**Spark’s Take on DRTS Stock**

According to Spark, TipRanks’ AI Analyst, DRTS is a Neutral.

The score is held down primarily by very weak financial performance (no revenue, widening losses, and significant ongoing cash burn) and limited valuation support (negative P/E, no dividend yield provided). This is partially offset by constructive technical trend signals, with the stock trading above its 20/50/100/200-day moving averages.

To see Spark’s full report on DRTS stock,  
click here.

**More about Alpha Tau Medical Ltd**

**YTD Price Performance:** 174.24%

**Average Trading Volume:** 854,041

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $1.16B

### Related Stocks

- [DRTS.US](https://longbridge.com/en/quote/DRTS.US.md)
- [DRTSW.US](https://longbridge.com/en/quote/DRTSW.US.md)

## Related News & Research

- [Alpha Tau Medical CFO Raphi Levy disposes of USD 220,002 Alpha Tau Medical common shares](https://longbridge.com/en/news/290964114.md)
- [Alpha Tau treats first recurrent glioblastoma patient in Israel with Alpha DaRT under broad-access study](https://longbridge.com/en/news/290563323.md)
- [CFO’s Bold Stock Move Sends Fresh Signals at Alpha Tau Medical](https://longbridge.com/en/news/291610506.md)
- [Alpha Tau Medical shareholders approve CEO Sofer to remain board chair](https://longbridge.com/en/news/290873899.md)
- [Alpha Tau Medical CFO Raphi Levy sells 20,000 shares for $240,044](https://longbridge.com/en/news/291414601.md)